ARQT icon

Arcutis Biotherapeutics

280 hedge funds and large institutions have $3.76B invested in Arcutis Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 73 funds opening new positions, 102 increasing their positions, 76 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
280
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$21.1M
Puts
$2.6M
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CA
276
Clearstead Advisors
Ohio
$581
MCM
277
MAI Capital Management
Ohio
$465
PA
278
Parallel Advisors
California
$58
RFP
279
Root Financial Partners
California
$29
TC
280
Tejara Capital
United Kingdom
PHS
281
PFM Health Sciences
California
JGC
282
J. Goldman & Co
New York
SAM
283
Simplify Asset Management
Nevada
ABG
284
Ally Bridge Group
New York
APM
285
Avidity Partners Management
Texas
VPC
286
Vestal Point Capital
New York
SSA
287
Schonfeld Strategic Advisors
New York
Stifel Financial
288
Stifel Financial
Missouri
CCIA
289
Campbell & Co Investment Adviser
Maryland
YIH
290
Y-Intercept (HK)
Hong Kong
GCM
291
Graham Capital Management
Connecticut
DC
292
Diametric Capital
Massachusetts
BHCM
293
Brevan Howard Capital Management
Jersey
BCM
294
Bayesian Capital Management
New York
TI
295
Trexquant Investment
Connecticut
OAC
296
OMERS Administration Corp
Ontario, Canada
PA
297
PharVision Advisers
Florida
CPC
298
Cookson Peirce & Co
Pennsylvania
WC
299
Wexford Capital
Florida
FDCDDQ
300
Federation des caisses Desjardins du Quebec
Quebec, Canada